Clinical Trial Update: A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) [Phase 1]

View source ↗

Summary

This is a Phase 1 trial update evaluating JNJ-80948543 in combination with other CD3 T-cell engagers for relapsed or refractory B-cell non-Hodgkin lymphoma, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• JNJ-80948543 (JNJ-80948543)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: ACTIVE_NOT_RECRUITING